Minoryx Therapeutic

Minoryx

This biotechnology company develops orphan drugs and therapies for patients suffering from rare, life-threatening genetic diseases of the central nervous system.

Minoryx Therapeutics

This company develops leriglitazone, a pharmacological treatment for patients with rare genetic central nervous system diseases such as X-linked adrenoleukodystrophy.

Noema Pharma

This company develops clinical-stage therapeutic products for patients with central nervous system disorders and orphan neurological conditions.

Pheno Therapeutics

This biotech company develops neuroprotective and remyelinating therapies for patients with multiple sclerosis and other neurodegenerative disorders.

MindImmune Therapeutics

This company develops monoclonal antibody therapeutics to treat neurodegenerative diseases and neuroinflammation for patients with central nervous system disorders.

Mahzi Therapeutics

This biotechnology company develops gene and antisense oligonucleotide therapies for patients with rare genetic neurodevelopmental disorders.

Convelo Therapeutics

This biotechnology company develops medicines to regenerate nerve cell myelin for patients with neurological disorders, including multiple sclerosis and paediatric leukodystrophies.

Comet Therapeutics

This biotechnology company develops coenzyme A metabolism therapies to treat patients with inherited metabolic diseases and orphan neurological disorders.